A5067089190- Multiple Sclerosis Research Studies
- Polyomavirus and related diseases
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Genetic Neurodegenerative Diseases
- Peripheral Neuropathies and Disorders
- Systemic Sclerosis and Related Diseases
- Neurological diseases and metabolism
- Effects of Vibration on Health
- Mitochondrial Function and Pathology
- Fungal Plant Pathogen Control
- Powdery Mildew Fungal Diseases
Oulu University Hospital
2021-2025
University of Oulu
2021-2025
Finland University
2025
Cladribine tablets for adult patients with highly active relapsing multiple sclerosis (MS) have been available in Finland since 2018. Real-world data from different genetic and geographical backgrounds are needed to complement clinical trials.We investigated the use of cladribine a non-interventional cohort study, based on real-world nationwide Finnish MS registry. All eligible who had initiated treatment 2018-2020 were included. Descriptive analyses outcomes conducted using summary...
ABSTRACT Background The treatment of relapsing‐remitting multiple sclerosis (RRMS) is changing. There are limited data about initial RRMS in Finland. Objective Our objectives were to study the trends disease‐modifying treatments (DMTs) for patients with from 2013 2022, delays, factors associated DMT choice, switch patterns, and effect COVID‐19 pandemic. Methods This retrospective register used secondary Finnish MS register. DMTs classified into medium‐efficacy (meDMTs; beta interferons,...
To characterize patient-perceived fatigue by using the Finnish Multiple Sclerosis (MS) registry data. Fatigue was assessed with Severity Scale (FSS), for Motor and Cognitive Functions (FSMC), Visual Analogue Scale-Fatigue. Disease severity evaluated Expanded Disability Status symptoms Scales. Patient reported outcomes (PROs) included Neuropsychological Questionnaire, Euro Quality of Life - 5 dimensions, 15 D, Impact Scale. For purposes study, patients were classified to those without (FSS ≤...
The genetics of cerebellar ataxia is complex. Hundreds causative genes have been identified, but only a few cause more than single cases. spectrum ataxia-causing differs considerably between populations. aim the study was to investigate molecular epidemiology in Finnish population.All patients hospital database were reviewed for diagnosis unspecified ataxia. Acquired ataxias and nongenetic such as those related infection, trauma or stroke excluded. Sixty with sporadic unknown etiology 36...
Alemtuzumab is an effective disease-modifying therapy (DMT) for highly active multiple sclerosis (MS). However, safety concerns limit its use in clinical practice.To evaluate the of alemtuzumab a nationwide cohort Finnish MS patients.In this retrospective case series study, we analyzed data all but two patients who had received Finland until 2019. Data were systematically collected from patient files.Altogether 121 identified, most whom previous DMTs (82.6%). Median follow-up time after...
Background: Fatigue is a prominent and disabling symptom of multiple sclerosis (MS), impairing quality life. The disease course relapsing remitting MS (RRMS) individual.ObjectivesWe aimed to study the effects demographic clinical characteristics, as well lifestyle risk factors on experienced fatigue health-related life (HRQoL) among RRMS patients, comparing benign severe types.MethodsAltogether 198 Finnish patients were recruited for this real-life cross-sectional study. Self-reported...
<sec> <title>BACKGROUND</title> Digital patient registries are actively used in the monitoring of long-term diseases. The potential management symptoms is underutilized. </sec> <title>OBJECTIVE</title> present paper reports Finnish registry-based procedure to screen and manage cognitive fatigue multiple sclerosis (MS). data collected during first two years presented. <title>METHODS</title> Symbol Digit Modalities Test (SDMT), Multiple Sclerosis Neuropsychological Questionnaire (MSNQ),...